Oxymetholone treatment in myelofibrosis.

Area of Science:

• Hematology
• Oncology

Background:

• Advanced myelofibrosis is a serious bone marrow disorder.
• Patients often suffer from anemia, leukocytopenia, and thrombocytopenia.
• Hepatosplenomegaly and transfusion-dependent anemia are common complications.

Purpose of the Study:

• To evaluate the efficacy of oxymetholone therapy in patients with advanced myelofibrosis.
• To assess the impact of oxymetholone on hematological parameters and transfusion requirements.

Main Methods:

• A prospective multicenter study involving 11 patients with advanced myelofibrosis.
• Patients received long-term oxymetholone treatment at a dosage of 3-5 mg/kg body weight.
• Peripheral blood counts and transfusion needs were monitored.

Main Results:

• Significant improvements in hemoglobin and platelet counts were observed in 9 out of 15 treatment courses.
• The need for blood transfusions ceased completely in all 5 patients who previously required them.
• Treatment interruption resulted in relapse in 4 patients, with 2 responding to re-treatment.

Conclusions:

• Oxymetholone therapy shows potential benefit for advanced myelofibrosis, particularly in cases with transfusion-requiring anemia or severe thrombocytopenia.
• Androgen therapy may be a valuable option for managing hematological complications in myelofibrosis.
• Further research is warranted to establish optimal treatment protocols and long-term outcomes.